Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great attitude !!
Yep! We need that volume for NNVC!
You should check the Dolomites!
The market is down in general.
NNVC too!
I could be wrong but I think that We will have better results around March!
Knowing that, February will be a good month to invest!
I don't think that we will see the stock that low again after that.
So let's get ready !
FN
Agreed!
Yesterday we were way down and back to 4.80 in the last hour.
Great post changes_iv!
And your videos are informative !
FN
Good! Hopefuly we are going to hear fro him.
I got it after my reply!
I cannot wait to meet you in Hawaii!
We will have fun!
FN
I am black too!
Oh! I see what you are saying!
I think it's 1.37 for 4.80.
Thanks Puffer.
Leif
How is he doing?
Thanks Echo!
Thanks Echo!
Great question !
Do you think that you could email him And comeback to us!
That would be great!
Thanks
FN
You are well come noretreat!
Email exchange with Dr Seymour:
Do you think that the plant will be finished in March or sooner?
Let's say by the end of the quarter although I think it will be sooner
Then what will happen?
We move it and start making batches in parallel to the existing facility
Some people think that the clinical trial will start in the middle of 2015.
I think that it will be much earlier but that's out of our control
A lot of us really believe in NNVC 's success , but the frustration is that the dates keep changing .
Actually, with all the money we have, things will go faster
Form 8-K for NANOVIRICIDES, INC.
24-Jan-2014
Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Item 1.01. Entry into a Material Definitive Agreement.
On January 21, 2014, the Registrant entered into a Securities Purchase Agreement (the "Agreement") with certain purchasers (the "Purchasers"), relating to the offering and sale (the "Offering") of units ("Units") at the aggregate purchase price of $5.25 ("Purchase Price") per Unit. The price per Unit was equal to a four percent (4%) discount to the 20-day VWAP of the Registrant's stock price on Friday, January 17, 2014. The exercise price of the Warrant was equal to the closing price of the Registrant's stock on Friday, January 17, 2014. Each Unit consisted of one share of the Company's common stock, par value $0.001 per share (the "Common Stock") and Sixty-Five Hundredths (65/100) of a warrant to purchase one share of Common Stock ("Warrant"), issuable upon exercise of the Warrant at the exercise price of $6.05 per share (the "Warrant Shares", collectively with the Units, Common Stock and Warrant, the "Securities"). The Warrants are exercisable immediately and expire five years after issuance.
On January 24, 2014, the Company and the Purchasers consummated the purchase and sale of the Securities (the "Closing") of 3,815,285 shares of Common Stock and 2,479,935 Warrants, and the Company raised gross proceeds of $20,030,246.25 before estimated expenses of the Offering of approximately $1,200,000, which includes placement agent fees but does not include and attorneys' fees and other expenses. The Company intends to use the proceeds for general business purposes and expects that it will be able to accelerate the development of its drug candidate pipeline with this additional funding.
The Agreement contains representations and warranties and covenants for each party, which must be true and have been performed at Closing. Additionally, the Company has agreed to indemnify and hold harmless the Purchasers and their related parties against certain liabilities in connection with the issuance and sale of the Securities under the Agreement.
The Offering is made pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-184626), which was declared effective by the Securities and Exchange Commission on December 21, 2012 and Form S-3MEF (File No. 333-193439). The Company, pursuant to Rule 424(b) under the Securities Act of 1933, has filed with the Securities and Exchange Commission a prospectus supplement relating to the Offering.
In connection with the Offering, pursuant to a Placement Agency Agreement dated January 20, 2014 among Midtown Partners & Co., LLC and Chardan Capital Markets, LLC (collectively, the "Placement Agents"), the Company paid the Placement Agents an aggregate cash fee representing 6% of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% of the number of shares of Common Stock sold in the Offering (the "Compensation Warrants") representing two percent of the Shares and substantially similar to the Warrants, at an exercise price equal to $6.05 per share. The Compensation Warrants will otherwise comply with FINRA Rule 5110(g)(1) in that for a period of six months after the issuance date of the Compensation Warrants, neither the Compensation Warrants nor any warrant shares issued upon exercise of the compensation warrants shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the Closing.
The foregoing is only a summary of the material terms of the Agreement and the Placement Agency Agreement. The foregoing description of the Agreement is qualified in its entirety by reference to the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference. The foregoing description of the Warrant is qualified in its entirety by reference to the Warrant, which is filed as Exhibit 10.2 to this Current Report on Form 8-K, which is incorporated herein by reference. The foregoing description of the Placement Agency Agreement is qualified in its entirety by reference to the Placement Agency Agreement which is filed as Exhibit 1.1 to this Current Report on Form 8-K, which is incorporated herein by reference.
This Current Report on Form 8-K contains forward-looking statements that involve risk and uncertainties. The risks and uncertainties involved include the substantial dilution to current stockholders as a result of the purchase price discount offered to the Purchasers, and the market overhang of shares available for sale that may develop as a result of the subsequent sale by the Purchasers of the shares of Common Stock underlying the Warrants and other shares it may acquire under the Agreement, as well as other risks detailed from time to time in the Company's periodic filings with the Securities and Exchange Commission.
Item 9.01 Financial Statement and Exhibits.
Exhibit
Number Description
1.1 Placement Agency Agreement, dated January 20, 2014, by and
between NanoViricides, Inc. and Midtown Partners & Co., LLC and
Chardan Capital Markets, LLC, as placement agents
10.1 Securities Purchase Agreement dated January 21, 2014 by and between
NanoViricides, Inc. and certain purchasers
10.2 Form of Common Stock Purchase Warrant
99.1 Press Release dated January 21, 2014
Thanks for passing by!
FN
Thanks for passing buy!
FN
Thanks!
Hey look when NNVC will be at 70
I hope to meet you in Hawaii !!
We have a lot to talk about!
And who knows becoming great friends!
FN
I love when you said "we"!
I love when you said "we"!
I give you that!
Am other guess for Tomorrow??
UP to 5.20!
FN
Nice!
I think that you owe me more than one peny!
Did you check the after hours ?
Wrong!
Today is up!
AMEX is doing good:
AMEX:
3-Month Highs: 22
3-Month Lows: 2
6-Month Highs: 14
6-Month Lows: 1
YTD Highs 47
YTD Lows 12
http://www.barchart.com/stocks/newhilo.php
Overall NYSE AMEX Nasdaq ETFs OTCBB Price
1-Month Highs 441 195 41 205 139 22 149 292 161 280
1-Month Lows 546 347 8 191 182 5 85 461 172 374
3-Month Highs 268 99 22 147 56 16 82 186 95 173
3-Month Lows 190 132 2 56 85 2 30 160 44 146
6-Month Highs 199 83 14 102 45 16 49 150 66 133
6-Month Lows 78 53 1 24 26 N/A 17 61 14 64
12-Month Highs 171 72 9 90 23 14 37 134 55 116
12-Month Lows 39 26 N/A 13 22 N/A 11 28 6 33
YTD Highs 490 222 47 221 171 22 159 331 188 302
YTD Lows 594 366 12 216 201 5 109 485 196 398
NNVC: 4.78 = 1.36 before the split.
Let's not forget that we were below a dollar few months ago.
It is good that we had a fall. The share price will rise and accomplish new highs.
FN
Maliman,
It will back up Tomorrow and down the day after!
OOPS!! JG36, sorry That message was for you:
True! But what matters is the work they are doing.
Now it is irelevant. If the share price drops at 4.50, this will give lots of opportunities to reinvest.
True! But what matters is the work they are doing.
Now it is irelevant. If the share price drops at 5.50, this will give lots of opportunities to reinvest.
Yes, but with this crazy Market, it could go back up very fast!
With the overnight sale of almost four million shares, NanoViricides' stock took a slide, and wrangling a part of the huge market will hang on its entire line of candidates.
NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic
January 22, 2014 | By Michael Gibney
SHARE
A nanoviricide mimics a target cell to kill a virus.--Courtesy of NanoViricides
Connecticut-based NanoViricides ($NNVC), with its novel antiviral nanotech delivery, pulled in $20 million in an offering from a combination of unnamed institutional investors and existing shareholders.
With now $40 million in hand, the company hopes to push its FluCide influenza treatment forward through early- and mid-stage trials and bring DengueCide into the clinic. Its Dengue candidate won orphan status from the FDA last summer.
NanoViricides' treatments are all based on the same technology, which uses nanoparticles with ligands on their surface that attract viruses, allowing the particle to encapsulate the virus and prevent it from infecting cells in the body. Along with its lead candidates, the company hopes to advance its HIV drug and ocular herpes drug into early trials, as well.
Sign up for our FREE newsletter for more news like this sent to your inbox!
"All of our drugs consist of two parts," CEO Eugene Seymour told FierceDrugDelivery. "We have a nanomicelle made of biodegradable nontoxic polymers and then, to make the drug unique for a particular virus, what we do is we mimic the protein that's expressed on the surface of that particular virus."
And with this mix-and-match kind of deliverability, it can take as few as a couple days to get a drug out in the open, Seymour said.
"Say I'm in Rwanda and I need a thousand doses of ebola," Seymour said. "We have that mimic protein in our library, we take that from our library, attach it to the nanomicelle out of the stockpile, and within a very short time, we have a drug."
So with a part of the new funding, NanoViricides will also begin scaling up its manufacturing process while at the same time performing toxicology studies for its strands in preparation to submit to the FDA. The company has plans to head to Australia for its initial trials.
According to its annual report filed in October, the total estimated market size for NanoViricides' candidates is over $40 billion, and potentially more depending on the success of its anti-influenza drug. With the overnight sale of almost four million shares, NanoViricides' stock took a slide, and wrangling a part of the huge market will hang on its entire line of candidates.
Among its development products, it has injectables designed to treat epidemic influenza H1N1, H5N1 and avian influenzas; an HIV treatment; eye drops for conjunctivitis and keratitis; drugs for oral and genital herpes; and its dengue candidate. In early research, it has programs for the MERS CoV virus, rabies, ebola/Marburg and other viral hemorrhagic fevers, according to the report.
"This is going to be a major lifesaver," Seymour said. "For flu, I suspect there are a million people hospitalized between the U.S. and the EU, and about 200,000 people die."
The company is now looking to hire, Seymour said, "as many people as we can find" to get its candidates submitted to the FDA as soon as possible.
- here's the release
Related Articles:
Virus-killing nanoviricides win orphan status for dengue fever
NanoViricides anti-Dengue drugs effective in new study
Read more: NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic - FierceDrugDelivery http://www.fiercedrugdelivery.com/story/nanoviricides-snags-20m-offering-push-virus-killing-nanotech-flu-dengue-thr/2014-01-22#ixzz2r9JDdUy8
Subscribe at FierceDrugDelivery
wow !
You know a lot!
I hear you, but until we have a deal, I don't think that investors will seriously invest in it.
They are waiting for the "GO" from the FDA.
We might be at $10 or $15 when the building will be ready, and when we will start te clinical trials.
But until then it's only an exciting money game.
Sit tight on your chairs!!
(That also, was for Weedie !!)
FN
And, next week we will be back at 6.00